These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8667054)

  • 41. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients.
    Zhang H; Tian M; Li S; Liu J; Tanada S; Endo K
    Cancer Biother Radiopharm; 2003 Oct; 18(5):719-26. PubMed ID: 14629820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma.
    De Winter F; Brans B; Van De Wiele C; Dierckx RA
    Clin Nucl Med; 1999 Nov; 24(11):898-9. PubMed ID: 10551482
    [No Abstract]   [Full Text] [Related]  

  • 43. Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
    Liepe K; Kropp J; Hliscs R; Franke WG
    Clin Nucl Med; 2000 Nov; 25(11):901-4. PubMed ID: 11079588
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)].
    Holle LH; Humke U; Trampert L; Ziegler M; Kirsch CM; Oberhausen E
    Urologe A; 1997 Nov; 36(6):540-7. PubMed ID: 9487590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer.
    Limouris G; Shukla SK; Manetou A; Kouvaris I; Plataniotis G; Triantafyllou N; Rigas AV; Vlahos L
    Anticancer Res; 1997; 17(3B):1699-704. PubMed ID: 9179222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantifying leukocyte and thrombocyte suppression-recovery after Re-186 HEDP for bone metastases.
    Spencer RP
    Clin Nucl Med; 2000 Jun; 25(6):405-6. PubMed ID: 10836683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
    Pandit-Taskar N; Batraki M; Divgi CR
    J Nucl Med; 2004 Aug; 45(8):1358-65. PubMed ID: 15299062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP.
    Palmedo H; Grünwald F; Wagner U; Köhler S; Krebs D; Biersack HJ
    Clin Nucl Med; 1998 Aug; 23(8):501-4. PubMed ID: 9712380
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radiolabeled bone-seeking radiopharmaceuticals.
    Atkins HL; Srivastava SC
    Q J Nucl Med; 1996 Sep; 40(3):285-9. PubMed ID: 8961805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pain palliation and nuclear medicine.
    McEwan AJ
    Eur J Nucl Med; 1993 Jan; 20(1):1-3. PubMed ID: 7678395
    [No Abstract]   [Full Text] [Related]  

  • 52. Rhenium-188(Sn)HEDP for treatment of osseous metastases.
    Maxon HR; Schroder LE; Washburn LC; Thomas SR; Samaratunga RC; Biniakiewicz D; Moulton JS; Cummings D; Ehrhardt GJ; Morris V
    J Nucl Med; 1998 Apr; 39(4):659-63. PubMed ID: 9544677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Palliative treatment of bone metastases with bone-seeking radionuclides].
    De Klerk JM; Zonnenberg BA; Huiskes AW; Han SH; Blijham GH; Van Rijk PP
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2618-22. PubMed ID: 10028362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
    Koutsikos J; Leondi A
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1392-3; author reply 1394-5. PubMed ID: 18438661
    [No Abstract]   [Full Text] [Related]  

  • 55. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate.
    Israel O; Keidar Z; Rubinov R; Iosilevski G; Frenkel A; Kuten A; Betman L; Kolodny GM; Yarnitsky D; Front D
    J Clin Oncol; 2000 Jul; 18(14):2747-54. PubMed ID: 10894875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Palliative radiotherapy of bone metastases. Comparison between 2 fractionations].
    Peretti G; Belfiore G; Nuzzo A; Morera E; Basilico L
    Radiol Med; 1984 Jun; 70(6):393-5. PubMed ID: 6085411
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
    Liepe K; Geidel HH; Bergmann R; Haase M; Runge R; Kotzerke J
    Nucl Med Commun; 2009 Sep; 30(9):693-9. PubMed ID: 19528873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases.
    Cheng A; Chen S; Zhang Y; Yin D; Dong M
    Cancer Biother Radiopharm; 2011 Apr; 26(2):237-44. PubMed ID: 21539455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radiopharmaceuticals in clinical trials.
    Holmes RA
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):22-6. PubMed ID: 7684861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.